EXCISION BIOTHERAPEUTICS
๐บ๐ธUnited States
Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
Phase 1
- Conditions
- HIV-1-infection
- Interventions
- Biological: EBT-101
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Excision BioTherapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT05143307
- Locations
- ๐บ๐ธ
Quest Clinical Research, San Francisco, California, United States
๐บ๐ธWashington University, Saint Louis, Missouri, United States
๐บ๐ธCooper Health, Camden, New Jersey, United States
Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Excision BioTherapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT05144386
- Locations
- ๐บ๐ธ
Washington University, Saint Louis, Missouri, United States
๐บ๐ธQuest Clinical Research, San Francisco, California, United States
๐บ๐ธCooper Health, Camden, New Jersey, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath